TECHNOLOGY FOR BUSINESSDATACLOUDPLATFORMSAI

AI · 9 MIN READ

Biomedical World Model with Self-Evolving Multimodal Agents

I recently read an interesting preprint on STELLA: Towards a Biomedical World Model with Self-Evolving Multimodal Agents, and it gave me a clearer picture of where AI in life sciences may be heading.

Until recently, most people viewed AI in biomedical research as a support tool. It could summarize papers, explain genes, help write Python scripts, generate hypotheses, or assist with literature review.

But STELLA represents a more advanced direction.

It is not just a chatbot that answers biomedical questions. It is designed as a self-evolving multimodal biomedical agent system that can reason, create tools, run computational workflows, evaluate its own results, learn from feedback, and connect predictions with experimental validation.

In simple terms, STELLA is trying to move from being an AI assistant to becoming an AI research partner.

And this is a very important shift.

Why traditional AI systems are not enough for biomedical research

Biomedical research is complex because it is not a single-step reasoning problem.

A real research question may require:

  • reading scientific literature

  • querying biomedical databases

  • analyzing gene expression data

  • understanding protein structures

  • checking pathway and disease associations

  • designing mutations

  • running simulations

  • generating code

  • interpreting biological results

  • validating hypotheses in the wet lab


A normal LLM may understand the language around these tasks, but it often lacks three important capabilities:

  1. It cannot reliably execute the full scientific workflow.

  2. It depends on a fixed set of tools or static knowledge.

  3. It does not improve its research strategy through experimental feedback.

This is where agentic AI becomes interesting.

Instead of treating AI as a single model that gives one answer, agentic systems break a complex problem into multiple roles, tools, actions, validations, and feedback loops.

That is the core idea behind STELLA.

The agentic architecture behind STELLA

Article content

Conceptual view of how STELLA interacts with the biomedical research environment.

STELLA uses a collaborative multi-agent design. Each agent has a specific role in the research pipeline.

1. Manager Agent

The Manager Agent acts like the research planner. It receives a high-level biomedical goal and converts it into a structured research workflow.

For example, instead of simply answering:

“Find a novel target for NK-cell therapy in AML”

the Manager Agent can break the problem into steps such as:

  • define the disease and phenotype context

  • identify candidate genes or proteins

  • search relevant databases

  • analyze pathway and network evidence

  • filter already-known targets

  • rank novel candidates

  • prepare a biological rationale

This is similar to how a senior scientist or research lead would design an investigation.

2. Developer Agent

The Developer Agent is the execution layer.

It writes and runs code, usually Python-based workflows, to perform actual bioinformatics analysis.

This is important because serious biomedical research cannot rely only on natural language reasoning. It needs executable pipelines.

The Developer Agent can work with datasets, scripts, APIs, model outputs, and analysis tools. It turns the research plan into computational action.

In software engineering terms, this is where the agent moves from “thinking” to “doing.”

3. Critic Agent

The Critic Agent evaluates intermediate outputs. This is one of the most important parts of the architecture.

In real research, the first result is often incomplete, weak, or biologically unconvincing. A good scientist does not stop at the first answer. They ask:

  • Is this result actionable?

  • Is the biological logic strong enough?

  • Are we only describing correlation?

  • Do we need mechanistic evidence?

  • Do we need another database, model, or experiment?

  • Are we missing a better explanation?

The Critic Agent plays this role. It reviews results, identifies gaps, and pushes the system to refine the workflow. This makes the pipeline more robust than a one-shot LLM answer.

4. Tool Creation Agent

The Tool Creation Agent is what makes STELLA especially interesting.

Most AI agents depend on prebuilt tools. But biomedical research constantly changes. New databases, new APIs, new models, and new experimental methods appear all the time.

A fixed toolkit becomes outdated quickly.

STELLA addresses this through a dynamic Tool Ocean.

When the system identifies that it lacks a required capability, the Tool Creation Agent can discover, wrap, validate, and integrate new tools.

This may include tools for:

  • disease-gene association queries

  • CRISPR or RNAi dependency analysis

  • protein-DNA interaction analysis

  • restriction enzyme analysis

  • protein structure prediction

  • single-cell data interpretation

  • pathway and network analysis

  • custom biomedical database access

This is a key idea: the agent does not only use tools; it can expand its own tool ecosystem.

That is a big step toward self-evolving AI systems.

Template Library: how the agent learns from successful workflows

Another powerful concept in STELLA is the Template Library. When a research workflow succeeds, STELLA can store the reasoning pattern as a reusable template.

For example, if a workflow successfully moves from:

disease context → candidate genes → pathway evidence → patient dataset validation → target ranking

then this strategy can be reused for future target discovery tasks.

This is similar to how experienced researchers build mental models over time. A beginner sees each task as new. An expert recognizes patterns.

STELLA attempts to capture these successful patterns and reuse them.

This means the system is not only executing tasks. It is gradually improving its own research process.

Agentic pipeline: from question to scientific hypothesis

The most interesting part of STELLA is the full agentic pipeline.

A simplified version looks like this:

User goal → Manager planning → Tool selection → Code execution → Result evaluation → Tool creation if needed → Re-analysis → Hypothesis generation → Wet-lab validation → Feedback into the system

This is very different from a normal chatbot workflow.

A chatbot usually does:

Question → Answer

An agentic biomedical system does:

Question → Plan → Tools → Execution → Critique → Iteration → Evidence → Validation → Learning

That is closer to how real scientific discovery works.

Example 1: Discovering a new NK-cell target in AML

One of the paper’s strongest examples is in cancer immunology.

STELLA was asked to identify novel, previously unreported negative regulators of NK-cell function in the context of acute myeloid leukemia, or AML.

NK cells are important immune cells that can kill cancer cells. But in AML, their activity can be suppressed by inhibitory signals from tumor cells and the microenvironment.

STELLA used its reasoning templates and biomedical tools to search literature, databases, regulatory networks, and patient evidence.

It then ranked candidate genes and identified BTN3A1 as a promising negative regulator of NK-cell function.

The important part is that this was not just a theoretical prediction.

The researchers validated it experimentally.

They used CRISPR knockout in NK92MI cells and tested the effect against multiple AML cell lines. The result was that loss of BTN3A1 increased NK-cell cytotoxicity and degranulation.

This is a strong example of an agentic AI system supporting the complete research loop:

hypothesis generation → candidate prioritization → experimental validation

Example 2: Enzyme engineering with iterative feedback

The second important example is protein engineering.

STELLA was used to optimize strictosidine synthase, an enzyme involved in biosynthesis of terpenoid indole alkaloids, which are connected to medically valuable compounds.

The agentic pipeline here involved:

  • retrieving enzyme and substrate information

  • predicting enzyme-substrate structures

  • identifying catalytic pocket residues

  • generating a virtual mutant library

  • predicting activity using a protein language model

  • filtering variants using stability calculations

  • recommending mutations for wet-lab testing

  • using experimental feedback to improve the next round

This is very close to a closed-loop engineering system.

Instead of manually testing random mutations, the agent guides the search through computational prediction, structural reasoning, and experimental feedback.

One highlighted variant, M276L, showed more than a two-fold improvement in catalytic activity.

This is important because it shows that agentic AI can be useful not only for analyzing biology, but also for designing better biological systems.

Example 3: From computational intelligence to physical lab intelligence

The third part of STELLA moves into robotics.

This is where the idea of a “Biomedical World Model” becomes more ambitious.

The system works with Vision-Language-Action models, or VLA models, for biomedical lab tasks.

These tasks are not easy.

A robot in a lab needs to handle:

  • pipettes

  • centrifuge tubes

  • digital panels

  • transparent containers

  • liquid levels

  • rotating knobs

  • tube caps

  • precise placement tasks

STELLA uses a Decompose-Monitor-Recover mechanism.

This means the task is broken into smaller subtasks.

For example, screwing a centrifuge tube cap may be decomposed into:

  1. grasp the tube

  2. align the cap

  3. engage the thread

  4. tighten the cap

During execution, the system monitors whether each step is going correctly. If a failure happens, it uses recovery tools to correct the mistake.

Those recovery attempts then become training data for improving the VLA model. This is a powerful idea. The system learns not only from successful demonstrations, but also from failures and recoveries. That is closer to how humans learn physical skills.

Why this matters for engineers

As a software engineer learning bioinformatics, I find this direction very exciting.

Because the future of biomedical AI will not be only about biology knowledge.

It will need engineering skills such as:

  • data pipelines

  • API integration

  • distributed systems

  • agent orchestration

  • workflow automation

  • Python-based scientific computing

  • database querying

  • model evaluation

  • cloud-native infrastructure

  • reproducible research environments

  • human-in-the-loop validation

In many ways, agentic biomedical systems look like advanced software platforms.

They combine AI models, tools, data, execution environments, feedback loops, and observability.

For engineers, this creates a huge opportunity.

The next generation of biomedical platforms may need people who understand both:

software architecture and scientific workflows

The bigger picture: AI systems that evolve with science

The most important takeaway from STELLA is not that one model performed well on a benchmark.

The bigger takeaway is this:

The future may belong to AI systems that can continuously evolve with the scientific environment.

A static AI model is limited by its training data.

But a self-evolving agent can:

  • learn from successful workflows

  • create new tools

  • call external databases

  • execute code

  • critique its own outputs

  • incorporate experimental feedback

  • improve future decision-making

This makes the system more adaptable.

And adaptability is critical in biomedicine, because biology is complex, noisy, and constantly changing.

But we should be careful

Biomedical AI also requires strong human oversight.

A system that proposes targets, mutations, or experimental strategies must be evaluated carefully. Wrong conclusions in biomedical research can waste resources or even create safety risks if moved too quickly toward clinical use.

So the right framing is not:

“AI will replace scientists.”

The better framing is:

“Agentic AI may become a powerful research partner for scientists.”

My takeaway

STELLA gives us a glimpse of how AI could transform biomedical research.

Not as a simple question-answering system.

But as a self-evolving research engine that can:

  • plan scientific workflows

  • create and use tools

  • execute bioinformatics pipelines

  • evaluate intermediate results

  • generate hypotheses

  • connect computation with wet-lab validation

  • improve from feedback

  • support robotic lab execution

This is where AI becomes much more than a chatbot. It becomes an agentic system capable of participating in the scientific discovery process.

For someone coming from software engineering and exploring bioinformatics, this is extremely inspiring. It shows that the future of life sciences will need people who can build bridges between AI, biology, data engineering, automation, and real-world experimentation.

The next wave of impactful software may not only power apps and dashboards. It may power discovery pipelines, autonomous labs, and new biological insights.

Useful ideas for building better businesses with technology.

No spam. Only practical ideas about technology, products and business.